An open-label expanded access study of trifluridine/tipiracil for metastatic colorectal cancer.

被引：4
|
作者：
Mayer, Robert J.
Grothey, Axel
Hochster, Howard S.
Cohen, Steven J.
Vukovic, Vojislav M.
Makris, Lukas
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer
    Mayer, Robert J.
    Hochster, Howard S.
    Cohen, Steven J.
    Winkler, Robert
    Makris, Lukas
    Grothey, Axel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) : 961 - 969
  • [2] Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer
    Robert J. Mayer
    Howard S. Hochster
    Steven J. Cohen
    Robert Winkler
    Lukas Makris
    Axel Grothey
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 961 - 969
  • [3] The international open-label early-access study of trifluridine/tipiracil (TAS-102) in patients with pretreated metastatic colorectal cancer (phase IIIb)
    Alfredo, Falcone
    Jean-Francois, Seitz
    Timothy, Price
    Lucjan, Wyrwicz
    Alice, Dorbon
    Natividad, Lopez Busto
    Nadjat, Mounedji
    Eric, Van Cutsem
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Baseline characteristics in the international, open-label, early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb).
    Price, Timothy Jay
    Taieb, Julien
    Falcone, Alfredo
    Seitz, Jean Francois
    Wyrwicz, Lucjan
    Becquart, Martin
    Moreno, Shanti
    Mounedji, Nadjat
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb)
    Falcone, Alfredo
    Taieb, Julien
    Price, Timothy Jay
    Seitz, Jean Francois
    Wyrwicz, Lucjan
    Becquart, Martin
    Moreno, Shanti
    Mounedji, Nadjat
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB)
    Price, T. J.
    Falcone, A.
    Chantrill, L.
    Horvath, L.
    Chua, Y. J.
    Burge, M.
    McLachlan, S-A
    Van Hazel, G.
    Pavlakis, N.
    Shapiro, J.
    Taieb, J.
    Seitz, J. F.
    Wyrwicz, L.
    Becquart, M.
    Moreno, S.
    Mounedji, N.
    Van Cutsem, E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 71 - 72
  • [7] Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer
    Celeste B. Burness
    Sean T. Duggan
    Drugs, 2016, 76 : 1393 - 1402
  • [8] Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer
    Burness, Celeste B.
    Duggan, Sean T.
    DRUGS, 2016, 76 (14) : 1393 - 1402
  • [9] Metastatic Colorectal Cancer Management with trifluridine/tipiracil
    White, Teresa
    Larson, Heidi
    Minnella, Alexandra
    Hochster, Howard S.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (02) : E30 - E37
  • [10] Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.
    Philip, Philip Agop
    Smaglo, Brandon George
    El-Rayes, Bassel F.
    Lesuisse, Christian
    Makris, Lukas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345